CD molecules 2006 — Human cell differentiation molecules

doi:10.1016/j.jim.2006.11.001

Journal of Immunological Methods

Volume 319, Issues 1–2, 30 January 2007, Pages 1-5

https://doi.org/10.1016/j.jim.2006.11.001 Get rights and content

Abstract

The Human Leucocyte Differentiation Antigens Workshops (HLDA) have since 1984 provided a forum for the characterization and study of leucocyte surface molecules and antibodies against them. HLDA devised the CD nomenclature, which is sanctioned by IUIS. The HLDA Council reviewed and modified the objectives of HLDA in 2004, and changed the name of the organization to Human Cell Differentiation Molecules (HCDM) to reflect the broader objectives. Workshop studies under the HCDM banner proceeded during 2005 and early 2006, culminating in a meeting in May 2006. At that meeting the Council, acting as Nomenclature Committee, approved a number of new CD designations and changes to some pre-existing CD designations, which are summarized in this report.

Introduction

The Human Leucocyte Differentiation Antigens Workshops (HLDA) have since 1984 provided a forum for the characterization and study of leucocyte surface molecules and antibodies against them (Bernard et al., 1984, Reinherz et al., 1985, McMichael et al., 1987, Knapp et al., 1989, Schlossman et al., 1995, Kishimoto et al., 1997, Mason et al., 2002, Zola et al., 2005). HLDA devised the CD nomenclature, which is sanctioned by the IUIS/WHO Nomenclature Committee (Boumsell, 1996, Zola et al., 2003). The HLDA Council reviewed and modified the objectives of HLDA in 2004, and changed the name of the organization to Human Cell Differentiation Molecules (HCDM) to reflect the broader objectives (Zola et al., 2005). Workshop studies under the HCDM banner proceeded during 2005 and early 2006, culminating in a meeting in May 2006.

The aims of this Workshop were defined more narrowly than previous HLDA Workshops, in part because of the short interval between the 8th HLDA and the first HCDM Workshop. Studies were not planned for multiple leucocyte lineages. The aims are summarized as follows:

•
Clarify and bring up to date earlier provisional (CDw) designations.
•
Fill in some of the CD numbers that had previously been reserved for members of molecule families such as chemokine receptors.
•
Allocate CD numbers to new antibodies and new molecules where adequate data was submitted.
•
Initiate multi-laboratory studies on important differentiation markers, irrespective of their cellular location. HCDM Council has previously decided that intracellular molecules that are useful markers of differentiation should be studied by the Workshops, although only surface membrane molecules will be given CD numbers (Zola et al., 2005). Studies on FOXP3 and Zap-70 were planned, because in each case there is an important application but there are disagreements on the best reagents or protocols. A specific question that merits analysis is the potential cross-reactivity of some of the Zap-70 reagents. We did not get enough Zap-70 reagents to do a worthwhile study, and the FOXP3 results were limited by the paucity of antibodies submitted.

Section snippets

Methods, results and discussion

Table 1 lists the existing CDw molecules which were re-classified as CD by the HCDM Council. Table 2 lists new CD assignments. These assignments were based on the Council's current rules for assigning a CD number, viz:

•
at least one Workshop — characterised antibody and good molecular data
•
the antigen is expressed on the surface of cells involved in immune reactions
•
the antibodies react with primary cells (not just transfectants or recombinant protein)
•
the antibody is available.

CD194 had previously

References (21)

A.H. Banham
Cell-surface IL-7 receptor expression facilitates the purification of FOXP3+ regulatory T cells
Trends Immunol.
(2006)
H.J. Bühring et al.
The receptor tyrosine kinase p185^HER2 is expressed on a subset of B-lymphoid blasts from patients with acute lymphoblastic leukemia and chronic myelogenous leukemia
Blood
(1995)
A.L. Jackson et al.
Restricted expression of p55 interleukin 2 receptor (CD25) on normal T cells
Clin. Immunol. Immunopathol.
(1990)
H. Zola et al.
CD molecules 2005: human cell differentiation molecules
Blood
(2005)
Battula, V.L., Bareiss, P.M., Treml, S., Conrad, S., Albert, I., Hojak, S., Abele, H., Schewe, B., Just, L., Skutella,...
L. Boumsell
The international workshops and conferences on human leukocyte differentiation antigens
Tissue Antigens
(1996)
Bühring, H.J., Battula, V.L., Treml, S., Schewe, B., Kanz, L., Vogel, W., in press. Novel markers for the prospective...
J. Harnaha et al.
Interleukin-7 is a survival factor for CD4+ CD25+ T-cells and is expressed by diabetes-suppressive dendritic cells
Diabetes
(2006)

There are more references available in the full text version of this article.

Cited by (109)

Receptor transfer between immune cells by autoantibody-enhanced, CD32-driven trogocytosis is hijacked by HIV-1 to infect resting CD4 T cells
2024, Cell Reports Medicine
Immune cell phenotyping frequently detects lineage-unrelated receptors. Here, we report that surface receptors can be transferred from primary macrophages to CD4 T cells and identify the Fcγ receptor CD32 as driver and cargo of this trogocytotic transfer. Filamentous CD32⁺ nanoprotrusions deposit distinct plasma membrane patches onto target T cells. Transferred receptors confer cell migration and adhesion properties, and macrophage-derived membrane patches render resting CD4 T cells susceptible to infection by serving as hotspots for HIV-1 binding. Antibodies that recognize T cell epitopes enhance CD32-mediated trogocytosis. Such autoreactive anti-HIV-1 envelope antibodies can be found in the blood of HIV-1 patients and, consistently, the percentage of CD32⁺ CD4 T cells is increased in their blood. This CD32-mediated, antigen-independent cell communication mode transiently expands the receptor repertoire and functionality of immune cells. HIV-1 hijacks this mechanism by triggering the generation of trogocytosis-promoting autoantibodies to gain access to immune cells critical to its persistence.
An autonomous microchip for real-time, label-free immune cell analysis
2023, Biosensors and Bioelectronics
Characterization of cell populations and identification of distinct subtypes based on surface markers are needed in a variety of applications from basic research and clinical assays to cell manufacturing. Conventional immunophenotyping techniques such as flow cytometry or fluorescence microscopy require immunolabeling of cells, expensive and complex instrumentation, skilled operators, and are therefore incompatible with field deployment and automated cell manufacturing systems. In this work, we introduce an autonomous microchip that can electronically quantify the immunophenotypical composition of a cell suspension. Our microchip identifies different cell subtypes by capturing each in different microfluidic chambers functionalized against the markers of the target populations. All on-chip activity is electronically monitored by an integrated sensor network, which informs an algorithm determining subpopulation fractions from chip-wide immunocapture statistics in real time. Moreover, optimal operational conditions within the chip are enforced through a closed-loop feedback control on the sensor data and the cell flow speed, and hence, the antibody-antigen interaction time is maintained within its optimal range for selective immunocapture. We apply our microchip to analyze a mixture of unlabeled CD4⁺ and CD8⁺ T cell sub-populations and then validated the results against flow cytometry measurements. The demonstrated capability to quantitatively analyze immune cells with no labels has the potential to enable not only autonomous biochip-based immunoassays for remote testing but also cell manufacturing bioreactors with built-in, adaptive quality control.
CC group of chemokines and associated gene expression of transcription factors: Deciphering immuno-pathogenetic aspect of oral submucous fibrosis
2023, Disease-a-Month
Oral submucous fibrosis (OSMF) is a chronic disease with significantly increasing malignant transformation rate. To date the pathogenesis of OSMF has been considered to be associated with areca nut constituents and their action on fibroblasts. However, fibrosis is also associated with immunological factors such as chemokines. In-depth analysis of such factors is the need of the hour in OSMF to better understand the pathogenesis so that effective therapeutic strategies can be developed in the future.
Clinically diagnosed cases of OSMF (n=21) and healthy individuals (n=10) were enrolled in the present study. Chemokines such as CCL2, CCL3, CCL4, CCL5, CCL11, CCL17, CCL28, CXCL1, CXCL5, CXCL8, CXCL9, CXCL10, and CXCL11 were assessed using the chemokine bead array in conjunction with the flow cytometry, along with real-time PCR (RT-PCR). The transcription factors CREB, NF-κB and NFAT5 were also studied for their expressions. The analysis of pg/ml (picogram/milliliter) values was done by using LEGENDplex™ Data Analysis Software.
The results obtained demonstrated early phase transient increase in CXCL-11, CCL20, CXCL9, CCL3, CCL2, CXCL10 and CXCL8. However, the expression of CCL3, CXCL10 and CXCL8 was higher in the late stage as compared to the early stage. The relative gene expression of CREB, NF-κB, NFAT5 were upregulated in the late stage of OSMF when compared to normal.
Distinctive sets of chemokine expression during the early and late stages of OSMF suggest a unique pattern of disease progression playing an important role in the pathogenesis.
Single nucleotide polymorphism patterns associated with a cancer resistant phenotype
2022, Experimental and Molecular Pathology
Citation Excerpt :
Several immune specific cell surface protein markers (cluster of differentiation markers (CD)) had unique WSB SNPs (Cd14,Cd151, Cd177, Cd1d2, Cd200r1, Cd200r2, Cd200r3, Cd200r4, Cd22, Cd244a, Cd248, Cd27, Cd274, Cd300a, Cd300c, Cd300e, Cd300lb, Cd300lf, Cd300lg, Cd320, Cd36, Cd4, Cd44, Cd55, Cd55b, Cd7, Cd72, Cd79b, Cd96, Cdc14b, Cdc42bpg, Cdc45 Cdc6, Cdca2, Cdca8, Cdh1). Expression of these proteins can enhance motility, invasion, and metastasis of cancer cells (Martin et al., 2020; Zola et al., 2007). WSB unique SNPs were found in metabolic and membrane function genes, and alterations in these functions are hallmarks of cancer (Hanahan and Weinberg, 2011).
In this study ten mouse strains representing ~90% of genetic diversity in laboratory mice (B6C3F1/J, C57BL/6J, C3H/HeJ, A/J, NOD.B1oSnH2/J, NZO/HILtJ, 129S1/SvImJ, WSB/EiJ, PWK/PhJ, CAST/EiJ) were examined to identify the mouse strain with the lowest incidence of cancer. The unique single polymorphisms (SNPs) associated with this low cancer incidence are reported.
Evaluations of cancer incidence in the 10 mouse strains were based on gross and microscopic diagnosis of tumors. Single nucleotide polymorphisms (SNPs) in the coding regions of the genome were derived from the respective mouse strains located in the Sanger mouse sequencing database and the B6C3F1/N genome from the National Toxicology Program (NTP).
The WSB strain had an overall lower incidence of both benign and malignant tumors compared to the other mouse strains. At 2 years, the incidence of total malignant tumors (Poly-3 incidence rate) ranged from 2% (WSB) to 92% (C3H) in males, and 14% (WSB) to 93% (NZO) in females, and the total incidence of benign and malignant tumor incidence ranged from 13% (WSB) to 99% (C3H) in males and 25% (WSB) to 96% (NOD) in females. Single nucleotide polymorphism (SNP) patterns were examined in the following strains: B6C3F1/N, C57BL/6J, C3H/HeJ, 129S1/SvImJ, A/J, NZO/HILtJ, CAST/EiJ, PWK/PhJ, and WSB/EiJ. We identified 7519 SNPs (involving 5751 Ensembl transcripts of 3453 Ensembl Genes) that resulted in a unique amino acid change in the coding region of the WSB strain.
The inherited genetic patterns in the WSB cancer-resistant mouse strain occurred in genes involved in multiple cell functions including mitochondria, metabolic, immune, and membrane-related cell functions. The unique SNP patterns in a cancer resistant mouse strain provides insights for understanding and developing strategies for cancer prevention.
Cold exposure aggravates pulmonary arterial hypertension through increased miR-146a-5p, miR-155-5p and cytokines TNF-α, IL-1β, and IL-6
2021, Life Sciences
Citation Excerpt :
Each RT-reaction used 1.5 μL from the 14 μL eluted RNA using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems; CA, USA). The mRNA expressions of Bmpr2, Smad5, Tgfbr2, Smad3, Cd68 and Cd163 (as surrogate for macrophage infiltration) [24,25], were determined using two-step RT-qPCR with random hexamers in combination with TaqMan probes from the Universal probe library (Roche; Basel, Switzerland) (see Table 1). Five hundred nanograms of extracted RNA were used for cDNA synthesis using QuantiNova Reverse Transcription Kit (Qiagen; Hilden, Germany).
Cold temperatures can aggravate pulmonary diseases and promote pulmonary arterial hypertension (PAH); however, the underlying mechanism has not been fully explored.
To explore the effect of chronic cold exposure on the production of inflammatory cytokines and microRNAs (miRNAs) in a monocrotaline (MCT)-induced PAH model.
Male Sprague Dawley rats were divided into a Control (23.5 ± 2 °C), Cold (5.0 ± 1 °C for ten days), MCT (60 mg/kg body weight i.p.), and MCT + Cold (ten days of cold exposure after 3 weeks of MCT injection). Hemodynamic parameters, right ventricle (RV) hypertrophy, and pulmonary arterial medial wall thickness were determined. IL-1β, IL-6, and TNF-α levels were determined using western blotting. miR-21-5p and -3p, miR-146a-5p and -3p, and miR-155-5p and -3p and plasma extracellular vesicles (EVs) and mRNA expression of Cd68, Cd163, Bmpr2, Smad5, Tgfbr2, and Smad3 were determined using RT-qPCR.
The MCT + Cold group had aggravated RV hypertrophy hemodynamic parameters, and pulmonary arterial medial wall thickness. In lungs of the MCT + Cold, group the protein levels of TNF-α, IL-1β, and IL-6 were higher than those in the MCT group. The mRNA expression of Cd68 and Cd163 were higher in the MCT + Cold group. miR-146a-5p and miR-155-5p levels were higher in the plasma EVs and lungs of the MCT + Cold group. Cold exposure promoted a greater decrease in miR-21-5p, Bmpr2, Smad5, Tgfbr2, and Smad3 mRNA expression in lungs of the MCT + Cold group.
Cold exposure aggravates MCT-induced PAH with an increase in inflammatory marker and miRNA levels in the plasma EVs and lungs.
THE EFFECTS OF ETANERCEPT AND CABERGOLINE ON ENDOMETRIOTIC IMPLANTS, UTERUS AND OVARIES IN RAT ENDOMETRIOSIS MODEL
2021, Journal of Reproductive Immunology
The pathophysiology of endometriosis is still unknown and treatment options remain controversial. Searches focus on angiogenesis, stem cells, immunologic and inflammatory factors. This study investigated the effects of etanercept and cabergoline on ovaries, ectopic, and eutopic endometrium in an endometriosis rat model. This randomized, placebo-controlled, blinded study included 50 rats, Co(control), Sh(Sham), Cb(cabergoline), E(etanercept), and E + Cb(etanercept + cabergoline) groups. After surgical induction of endometriosis, 2^nd operation was performed for endometriotic volume and AMH level. After 15 days of treatment: AMH level, flow cytometry, implant volume, histologic scores, immunohistochemical staining of ectopic, eutopic endometrium, and ovary were evaluated at 3^rd operation. All groups had significantly reduced volume, TNF-α, VEGF, and CD 146/PDGF-Rβ staining of endometriotic implants comparing to the Sh group (p < 0.05).TNF-α staining of eutopic endometrium in all treatment groups was similar to Sh and Co groups (p > 0.05). E and E + Cb groups significantly decreased TNF-α staining in the ovary comparing to Sh, Co, and Cb groups (p < 0.05). All treatment groups had significantly higher AFC compared to the Sh group. CD25⁺ Cells’ median percentage was significantly increased in the E + Cb group compared to Co, Sh, Cb, and E group. E + Cb group had a significantly higher CD5⁺ Cells’ level than the Co group (p = 0.035). In conclusion; Etanercept and/or Cabergoline decreased volume, TNF-α, VEGF, and CD 146/PDGF-Rβ staining of the ectopic endometrial implant. E and E + Cb treatment decreased TNF-α levels in the ovary. E + Cb also increased peripheral blood CD25⁺ & CD5⁺ Cell’s.

View all citing articles on Scopus

View full text

NomenclatureCD molecules 2006 — Human cell differentiation molecules

Abstract

Introduction

Section snippets

Methods, results and discussion

Trends Immunol.

Blood

Clin. Immunol. Immunopathol.

Blood

The international workshops and conferences on human leukocyte differentiation antigens

Tissue Antigens

Interleukin-7 is a survival factor for CD4+ CD25+ T-cells and is expressed by diabetes-suppressive dendritic cells

Diabetes

Nomenclature
CD molecules 2006 — Human cell differentiation molecules